For postmenopausal women who are not on hormone replacement therapy, this reduction can accelerate some symptoms of estrogen deficiency: vaginal dryness, sleep disruption, skin changes, joint aches
Tirzepatide (Zepbound) in the multi-dose KwikPen only
GLP-1: An emergent wonder anti-aging and longevity drug
These consultations allow monitoring of: Glycaemic control through HbA1c measurements (usually every 36 months) Weight changes and body composition Tolerability and adverse effects , particularly gastrointestinal symptoms Blood pressure and heart rate Renal function tests NICE recommends (NG28) that GLP-1 therapy should be continued only if there is demonstrable benefittypically defined as an HbA1c reduction of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months for diabetes indications

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect
Protection Against UV Damage: Glutathione injections help protect the skin against UV damage by neutralizing free radicals